Alzamend Neuro Inc. Common Stock

Alzamend Neuro Inc. an early clinical-stage biopharmaceutical company focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial which delivers a therapeutic combination of lithium proline and salicylate for the treatment of Alzheimer's bi-polar disorder post-traumatic stress disorder major depressive disorder other neurodegenerative diseases and psychiatric disorders; and AL002 that completed preclinical stage which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro Inc. was incorporated in 2016 and is headquartered in Atlanta Georgia.